Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | CARM1 | Q86X55 | 9/20 | 0.36 |
| ▸ | PRMT6 | Q96LA8 | 9/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2114252 | 0.89 | HRH1 (0.40) | NPC1HRH1CARM1PRMT6HRH3 | |
| SCHEMBL22477411 | 0.83 | HRH3 (0.45) | NPC1CARM1PRMT6HRH3TMEM97 | |
| SCHEMBL12464727 | 0.80 | GNAO1 (0.47) | NPC1 | |
| SCHEMBL22138607 | 0.80 | NPC1 (0.38) | NPC1CARM1PRMT6HRH3TMEM97 | |
| SCHEMBL17672834 | 0.80 | NPC1 (0.38) | NPC1CARM1PRMT6HRH3TMEM97 | |
| SCHEMBL26493872 | 0.79 | NPC1 (0.43) | SLC18A3NPC1HRH1CARM1PRMT6 | |
| SCHEMBL4569263 | 0.79 | SLC18A3 (0.43) | SLC18A3HRH1CARM1PRMT6ALDH1A1 | |
| SCHEMBL24658475 | 0.79 | GBA1 (0.36) | ALDH1A1KDM4E | |
| SCHEMBL25698067 | 0.79 | CCR5 (0.36) | NPC1CARM1PRMT6HRH3TMEM97 | |
| SCHEMBL7903518 | 0.79 | HRH3 (0.43) | NPC1CARM1PRMT6HRH3TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022173756-A1 | ANTIBACTERIAL COMPOUNDS | FORGE THERAPEUTICS, INC. (US) | 2022-08-18 | — | — | WO | disclosed |
| US-10000502-B2 | Substituted thiohydantoin derivatives as androgen receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-19 | — | — | US | disclosed |
| US-20170233401-A1 | SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-17 | — | — | US | disclosed |
| US-20110183938-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233401-A1 | SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS | AR, SHBG, NR5A1 | SLC18A3 1018/4885NPC1 981/4885HRH1 231/4885 |
| US-10000502-B2 | Substituted thiohydantoin derivatives as androgen receptor antagonists | AR, SHBG, NR5A1 | SLC18A3 1018/4885NPC1 981/4885HRH1 231/4885 |
| US-20110183938-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | CHEK1, CHEK2, BUB1B | SLC18A3 4303/4885NPC1 2505/4885HRH1 2178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.